B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
St. Petersburg State Pavlov Medical University
M.D. Anderson Cancer Center
Swiss Cancer Institute
University of California, Davis
University of Washington
Wake Forest University Health Sciences
University of Chicago
SCRI Development Innovations, LLC
University of Washington
UNC Lineberger Comprehensive Cancer Center
University of Arizona
University Hospital, Caen
Asan Medical Center
Jichi Medical University